Murielle E. Roussel - Publications

Liver stiffness in AL amyloidosis: interest in diagnosis and prognosis.

Journal: Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis

Published: September 06, 2026

Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.

Journal: American journal of hematology

Published: March 17, 2026

Engineering Soluble Recombinant BCMA for Ide-Cel Labeling.

Journal: European journal of immunology

Published: March 14, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Phase I(b) study evaluating the safety and efficacy of intratumoral agonistic anti-CD40 (selicrelumab) in combination with anti-PD-L1 (atezolizumab) in patients with refractory or relapsed B-cell lymphoma (ITSELF trial).

Journal: Immuno-oncology technology

Published: January 08, 2026

Monoclonal-related neuropathies: diagnosis, prognosis, and outcomes.

Journal: Hematology. American Society of Hematology. Education Program

Published: December 05, 2025

Comparison of patient, hospitalization and center characteristics from the EMMY centers, IFM centers, and all multiple myeloma centers in France.

Journal: Clinical hematology international

Published: December 04, 2025

35 years of academic trials focusing on high-dose therapy and autologous stem cell transplantation: the Intergroupe Francophone du Myélome (IFM) experience.

Journal: Blood cancer journal

Published: July 07, 2025

The Impact of Anti-CD38 Monoclonal Antibodies in Frontline Therapy for Patients With Newly Diagnosed Multiple Myeloma: Real-Life Results From the EMMY Study.

Journal: Clinical lymphoma, myeloma & leukemia

Published: July 03, 2025

Debulking strategy prior to anti-BCMA/CD3 bispecific antibodies in extramedullary and/or high tumor burden RRMM: a retrospective cohort study.

Journal: Blood cancer journal

Published: June 07, 2025

High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.

Journal: Blood

Published: May 15, 2025

Feasibility of carfilzomib infusions in hospital at home for patients with multiple myeloma (the Carfil-HAD study)

Journal: Bulletin du cancer

Published: April 25, 2025